Radiotherapy Archives – DHbriefs https://dhbriefs.com/cat_section/radiotherapy/ All about the European digital health ecosystem Sun, 04 Jun 2023 19:17:19 +0000 en-US hourly 1 https://wordpress.org/?v=6.8.8 Ariceum Therapeutics https://dhbriefs.com/dbentry/mr/ Sun, 04 Jun 2023 19:17:19 +0000 https://dhbriefs.com/?post_type=dbentry&p=9513 Ariceum Therapeutics is a clinical-stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. The name Ariceum is an anagram of “Marie Curie” whose discovery of radium and polonium have been huge contributions to finding treatments for cancer. Ariceum’s lead targeted systemic radiopharmaceutical product, 177Lu-satoreotide tetraxetan (“satoreotide”) ...

The post Ariceum Therapeutics appeared first on DHbriefs.

]]> Ariceum Therapeutics is a clinical-stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. The name Ariceum is an anagram of “Marie Curie” whose discovery of radium and polonium have been huge contributions to finding treatments for cancer. Ariceum’s lead targeted systemic radiopharmaceutical product, 177Lu-satoreotide tetraxetan (“satoreotide”) is an antagonist of the somatostatin type 2 (SST2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC), all of which have few treatment options and poor prognosis. Satoreotide is being developed as a “theranostic” pair for the combined diagnosis and targeted radionuclide treatment of these tumors.

The post Ariceum Therapeutics appeared first on DHbriefs.

]]> Oncocidia https://dhbriefs.com/dbentry/oncocidia/ Fri, 02 Jun 2023 09:10:11 +0000 https://dhbriefs.com/?post_type=dbentry&p=9465 The company is developing a targeted radiopharmaceutical cancer treatment called Oncocidia. This innovative treatment involves extending the already successful use of Iodine-131 in treating thyroid cancer to treat solid cancers (primary and metastatic) elsewhere in the body. Iodine-131 is used to label the necrosis avid agent hypericin. Hypericin targets necrosis in a tumor and carries ...

The post Oncocidia appeared first on DHbriefs.

]]> The company is developing a targeted radiopharmaceutical cancer treatment called Oncocidia. This innovative treatment involves extending the already successful use of Iodine-131 in treating thyroid cancer to treat solid cancers (primary and metastatic) elsewhere in the body. Iodine-131 is used to label the necrosis avid agent hypericin. Hypericin targets necrosis in a tumor and carries the therapeutic agent Iodine-131 to the tumor, where it is able to kill any remaining tumor cells by localized, short-range (2-3mm) beta irradiation. Oncocidia is administered in micro-dose quantities, minimizing chemotoxicities.

The post Oncocidia appeared first on DHbriefs.

]]> MVision AI https://dhbriefs.com/dbentry/mvision-ai/ Tue, 28 Mar 2023 13:09:14 +0000 https://dhbriefs.com/?post_type=dbentry&p=9064 MVision AI provides is a cloud-based software service provider for radiotherapy treatment planning. Its AI-powered automatic segmentation tool helps to standardize contouring and automate segmentation to streamline the radiotherapy treatment planning workflow. MVision’s deep learning model produces consistent contouring in minutes while maintaining the highest standards of quality for every patient, every time. As of ...

The post MVision AI appeared first on DHbriefs.

]]> MVision AI provides is a cloud-based software service provider for radiotherapy treatment planning. Its AI-powered automatic segmentation tool helps to standardize contouring and automate segmentation to streamline the radiotherapy treatment planning workflow. MVision’s deep learning model produces consistent contouring in minutes while maintaining the highest standards of quality for every patient, every time. As of March 2022, the company’s Guideline-Based Segmentation solution has been used for treating more than 100,000 cancer patients in 14 countries.

The post MVision AI appeared first on DHbriefs.

]]>